Top Analyst Upgrades and Downgrades: Epizyme, Goldcorp, GoPro, Intuitive Surgical, VMware and More

Print Email

Stocks were indicated lower after the Greek “no” vote on austerity. The one trend that has prevailed for over three years is that investors have literally bought every single pullback. 24/7 Wall St. reviews dozens of analyst and brokerage reports each morning of the week to find new trading and investing ideas for its readers. Some analyst calls cover stocks to buy, but others are about stocks to sell or avoid.

These are this Monday’s top analyst upgrades, downgrades and initiations.

Epizyme Inc. (NASDAQ: EPZM) was started as Outperform with a price target of $40 (versus a $22.71 close) at RBC Capital Markets. While this is a call to nearly double, Epizyme has a consensus price target of $38.67 and a 52-week range of $15.51 to $40.98.

Goldcorp Inc. (NYSE: GG) was started as Outperform with a price target of $24 (versus a $16.18 close) at Credit Suisse. Goldcorp has a consensus analyst target price of $24.19 and a 52-week range of $15.77 to $29.65.

GoPro Inc. (NASDAQ: GPRO) was started as Neutral with a price target of $60 (versus a $51.75 close) at Goldman Sachs. GoPro has a consensus price target of $69.25 and a 52-week range of $36.10 to $98.47.

Intuitive Surgical Inc. (NASDAQ: ISRG) was downgraded to Underweight from Equal Weight at Morgan Stanley, and the price target was cut to $500 from $560 (versus a $486.29 close). Intuitive Surgical has a consensus price target of $567.88 and a 52-week range of $376.00 to $559.04.

VMware Inc. (NYSE: VMW) Was downgraded to Market Perform from Outperform with a $90 price target (versus a $85.20 close) at FBR Capital Markets. VMware has a consensus analyst target of $96.10 and a 52-week range of $73.65 to $103.86.

ALSO READ: Why Investors and Analysts See AT&T as the Best Carrier Again

Other key analyst upgrades and downgrades this Monday were seen as follows: